Peripheral neuropathies under Immune Checkpoint Inhibitors: A pharmacovigilance study

被引：0
|
作者：
Ewig, E. [1 ]
Fournier, D. [1 ]
Palassin, P. [2 ]
Cholle, C. [3 ]
Bihan, B. [1 ]
Lebrun-Vignes, B. [1 ]
机构：
[1] GH Sorbonne Univ, Dept Pharmacol, Ctr Reg Pharmacovigilance Pitie St Antoine, AP HP, Paris, France
[2] CHU Montpellier, Ctr Reg Pharmacovigilance, Serv Pharmacol Medicale & Toxicol, Montpellier, France
[3] CHU Bordeaux, Ctr Reg Pharmacovigilance, Serv Pharmacol Medicale, Pole Sante Publ, Bordeaux, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
immune checkpoint inhibitors; peripheral neuropathy; pharmacovigilance;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-043
引用
收藏
页码：117 / 118
页数：2
相关论文
共 50 条
  • [1] Peripheral neuropathies associated with immune checkpoint inhibitors
    De Clerck, Lucie
    Balloy, Gaelle
    Peuvrel, Lucie
    Wiertlewski, Sandrine
    Pereon, Yann
    Magot, Armelle
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 528 - 528
  • [2] Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study
    Pascale Palassin
    Alexandre T. J. Maria
    Chayma Ladhari
    Xavier Quantin
    David Montani
    Arnaud Bourdin
    Clément Boissin
    Pierre Fesler
    Dominique Hillaire-Buys
    Philippe Guilpain
    Jean-Luc Faillie
    Cancer Immunology, Immunotherapy, 2022, 71 : 3093 - 3097
  • [3] Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study
    Xia, Shuang
    Gong, Hui
    Zhao, Yichang
    Guo, Lin
    Wang, Yikun
    Zhang, Bikui
    Sarangdhar, Mayur
    Noguchi, Yoshihiro
    Yan, Miao
    CANCERS, 2023, 15 (01)
  • [4] Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study
    Palassin, Pascale
    Maria, Alexandre T. J.
    Ladhari, Chayma
    Quantin, Xavier
    Montani, David
    Bourdin, Arnaud
    Boissin, Clement
    Fesler, Pierre
    Hillaire-Buys, Dominique
    Guilpain, Philippe
    Faillie, Jean-Luc
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (12) : 3093 - 3097
  • [5] Peripheral neuropathies after BRAF and/or MEK inhibitors treatment: A pharmacovigilance study
    Picca, A.
    Birzu, C.
    Berzero, G.
    Sanchez-Pena, P.
    Gaboriau, L.
    Vidil, F.
    Lenglet, T.
    Tafani, C.
    Ricard, D.
    Psimaras, D.
    Bihan, K.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 139 - 140
  • [6] The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study
    Yugo Chisaki
    Hiroki Hata
    Chikako Matsumura
    Yoshitaka Yano
    Therapeutic Innovation & Regulatory Science, 2022, 56 : 323 - 332
  • [7] The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study
    Chisaki, Yugo
    Hata, Hiroki
    Matsumura, Chikako
    Yano, Yoshitaka
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2022, 56 (02) : 323 - 332
  • [8] Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: A pharmacovigilance study
    Diaz, L.
    Dillies, A. C.
    Le Souder, C.
    Guilpain, P.
    Faillie, J. L.
    Maria, A.
    Palassin, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 149 - 149
  • [9] Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study
    Zhu, Jianhong
    Wu, Jialing
    Chen, Pengwei
    You, Kaiyun
    Su, Jianan
    Gao, Ziqing
    Bi, Zhuofei
    Feng, Min
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [10] Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
    Chen, Chenxin
    Chen, Ting
    Liang, Jizhou
    Guo, Xiaojing
    Xu, Jinfang
    Zheng, Yi
    Guo, Zhijian
    Chi, Lijie
    Wei, Lianhui
    Chen, Xiao
    Ye, Xiaofei
    He, Jia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345